Compounds > 3-(5-pyridin-2-yl-2h-tetrazol-2-yl)benzonitrile
Page last updated: 2024-11-12

3-(5-pyridin-2-yl-2h-tetrazol-2-yl)benzonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10198811
CHEMBL ID365499
SCHEMBL ID660355
MeSH IDM0482065

Synonyms (15)

Synonym
bdbm50151907
3-(5-pyridin-2-yl-tetrazol-2-yl)-benzonitrile
3-(5-pyridin-2-yltetrazol-2-yl)benzonitrile
CHEMBL365499 ,
AKOS015995227
507268-13-5
3-(5-(pyridin-2-yl)-2h-tetrazol-2-yl)benzonitrile
SCHEMBL660355
OGIBYDWBTRKAOL-UHFFFAOYSA-N
3-(5-pyridin-2-yl-2h-tetrazol-2-yl)benzonitrile
DTXSID70436690
J-510771
FT-0760671
A849647
PD180959

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This led to highly potent, selective and orally bioavailable 2-imidazolyl tetrazoles such as (10) that are devoid of cytochrome P450 inhibitory activity."( Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
Chapman, DP; Chung, J; Cosford, ND; Cramer, M; Green, M; Huang, D; King, C; Poon, SF; Roppe, JR; Smith, ND; Tehrani, L, 2004)		0.32

Dosage Studied

ExcerptRelevanceReference
"4 mg/kg (po) when dosed acutely."( Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
Anderson, J; Brodkin, J; Chung, J; Cosford, ND; Huang, D; Jiang, X; King, C; Munoz, B; Prasit, P; Roppe, J; Smith, ND; Tehrani, L; Varney, MA; Wang, B, 2004)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Translocator proteinRattus norvegicus (Norway rat)Ki0.18600.00010.65108.9300AID239658
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)IC50 (µMol)0.07300.00000.52627.9700AID255954
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)Ki0.16700.00050.19643.7600AID239476; AID239658; AID239660; AID254468
Metabotropic glutamate receptor 5Homo sapiens (human)IC50 (µMol)0.07150.00050.439410.0000AID248415; AID248795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)Activity3.80002.30003.05003.8000AID243309
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)Activity0.07300.00390.03840.0730AID250847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of DNA-templated transcriptionMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
phospholipase C-activating G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
learning or memoryMetabotropic glutamate receptor 5Homo sapiens (human)
learningMetabotropic glutamate receptor 5Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMetabotropic glutamate receptor 5Homo sapiens (human)
synapse organizationMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of calcium-mediated signalingMetabotropic glutamate receptor 5Homo sapiens (human)
cognitionMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
cellular response to amyloid-betaMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 5Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase activator activityMetabotropic glutamate receptor 5Homo sapiens (human)
A2A adenosine receptor bindingMetabotropic glutamate receptor 5Homo sapiens (human)
identical protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase bindingMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled receptor activity involved in regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
dendriteMetabotropic glutamate receptor 5Homo sapiens (human)
cytoplasmMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic spineMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic shaftMetabotropic glutamate receptor 5Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 5Homo sapiens (human)
Schaffer collateral - CA1 synapseMetabotropic glutamate receptor 5Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 5Homo sapiens (human)
postsynaptic density membraneMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID237068Half life in rat2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID236690Maximum concentration in rat when administered at 10 mg/kg perorally2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID246878In vivo receptor occupancy was determined in rats administered intraperitoneally after 1 hr2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID253817Half life in rat upon intravenous administration at a dose of 2 mg/kg; n = 22005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID236526Plasma clearance in rat2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID253613Volume of distribution in rat upon intravenous administration at a dose of 2 mg/kg; n = 22005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID253680Clearance in rat upon intravenous administration at a dose of 2 mg/kg; n = 22005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID237802Plasma level after 1 hr following 10 mg/kg dose administered intraperitoneally2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID236283Volume of distribution in rat2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID256425Ratio of compound levels in brain to that of plasma level was determined2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID256424Brain penetration measured by compound levels in brain at a dose of 10 mg/kg upon intraperitoneal after 1 hr2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID255954In vitro functional activity measured by changes in cytosolic [Ca2+] concentrations against rat metabotropic glutamate receptor 52005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID237385Plasma level after 1 hr following 10 mg/kg dose ip2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
AID237974Brain level after 1 hr following 10 mg/kg dose administered intraperitoneally2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID237365Level in rat brain after 1 hr following 10 mg/kg dose ip2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
AID256217Effective dose for maximum occupancy in rat upon intraperitoneal administration measured 1 hr post administration; n = 5 - 62005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID253565Oral bioavailability in rat (dose 10 mg/kg p.o.)2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID253722Maximum concentration in rat upon oral administration at a dose of 10 mg/kg; n = 32005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID248415Inhibitory concentration towards human glutamate receptor 5 in calcium flux assay2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID1063759Agonist activity at human alpha4beta2alpha5 nACHR expressed in HEK-tsA201 cells by fluorometric analysis2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for α4β2α5 nicotinic acetylcholine receptors.
AID239658Binding affinity towards Metabotropic glutamate receptor was determined by displacing [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine from rat cortical membranes2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
AID248795Antagonistic activity against Metabotropic glutamate receptor 5 in [Ca2+] flux assay using glutamate (10 uM) as agonist2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
AID247031Blockage of fear-conditioning in rats determined in the fear-potentiated startle (FPS) model of anxiety administered perorally after 1 hr2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID239660Binding affinity towards Metabotropic glutamate receptor was determined by displacing [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine from rat cortical membranes2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
AID235968Bioavailability in rat2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID256216Effective dose for maximum occupancy in rat upon oral administration measured 1 hr post administration; n = 6 - 72005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID256441Brain penetration measured by compound levels in plasma at a dose of 10 mg/kg upon intraperitoneal after 1 hr2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID243309Antagonistic activity against recombinant cytochrome P450 1A22004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
AID250847Antagonistic activity against Metabotropic glutamate receptor 5 in [Ca2+] flux assay using glutamate (10 uM) as agonist2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
AID243450Percent occupancy of the Metabotropic glutamate receptor 5 by the [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine ligand 1 hr post-administration of 10 mg/kg compound ip2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
AID243449Percent occupancy of the Metabotropic glutamate receptor 5 by the [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine ligand 1 hr post-administration of 10 mg/kg compound ip2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
AID254468Ability to displace [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine from binding to metabotropic glutamate receptor 5 in rat cortical membranes2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
AID246866In vivo receptor occupancy was determined in rats administered perorally after 30 min2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
AID1063766Positive allosteric modulation of human alpha4beta2alpha5 nACHR expressed in HEK-tsA201 cells assessed as potentiation of nicotine-induced current at 1 uM preincubated for 15 mins followed by nicotine-treatment by fluorometric analysis2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for α4β2α5 nicotinic acetylcholine receptors.
AID239476Displacement of [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine from glutamate 5 receptor of rat cortical membranes2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-fluoro-5-(5-pyridin-2-yl-2h-tetrazol-2-yl)benzonitrile
3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile: structure in first source		2.9340
ns 9283
3-(3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)benzonitrile: an alpha4beta2 nAChR agonist		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0210